MAZE insider transaction filings
Maze Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-08. Screen MAZE transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 19 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 37 legs across 15 filings by 4 insiders — 253,818 shares, $6,911,208 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 30,311 shares @ $29.95 ($907,921) by Coloma Jason V, filed 2026-07-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Coloma Jason V — Chief Executive Officer, Director | 5 | — | 16 legs · 153,999 sh · $4,183,016 | 2 |
| Bernstein Harold — President, R&D & CMO | 5 | — | 9 legs · 66,892 sh · $1,832,610 | 8 |
| Dandekar Atul — CSBO | 5 | — | 8 legs · 28,934 sh · $790,816 | 8 |
| Courtney Phillips — GC and Corp. Secretary | 2 | — | 4 legs · 3,993 sh · $104,766 | 2 |
| Johnson Paula A — Director | 1 | — | — | 1 |
| Kornowski Sophie — Director | 1 | — | — | 1 |
Recent Form 4 filings — Maze Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Bernstein Harold — President, R&D & CMO | Sale (S): 9,705 @ $26.22 | EDGAR |
| 2026-09-04 | 4 | Courtney Phillips — GC and Corp. Secretary | Sale (S): 1,738 @ $26.38 · Sale (S): 243 @ $27.12 · Sale (S): 1,990 @ $26.01 · Sale (S): 22 @ $25.78 | EDGAR |
| 2026-09-04 | 4 | Bernstein Harold — President, R&D & CMO | Sale (S): 4,481 @ $26.38 · Sale (S): 625 @ $27.12 · Sale (S): 5,130 @ $26.01 · Sale (S): 59 @ $25.78 | EDGAR |
| 2026-09-04 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 9,852 @ $26.38 · Sale (S): 1,375 @ $27.12 · Sale (S): 11,282 @ $26.01 · Sale (S): 129 @ $25.77 | EDGAR |
| 2026-09-04 | 4 | Dandekar Atul — CSBO | Sale (S): 2,800 @ $26.38 · Sale (S): 391 @ $27.12 · Sale (S): 3,207 @ $26.01 · Sale (S): 36 @ $25.81 | EDGAR |
| 2026-09-03 | 4 | Dandekar Atul — CSBO | Option exercise (M): 12,500 @ $0 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Courtney Phillips — GC and Corp. Secretary | Option exercise (M): 11,000 @ $0 · Option exercise (M): 11,000 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 2,593 @ $26.31 · Sale (S): 31,908 @ $26.29 · Option exercise (M): 50,000 @ $0 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 16,141 @ $10.42 · Sale (S): 16,141 @ $26.36 · Option exercise (M): 20,000 @ $0 · Option exercise (M): 16,141 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-08-31 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 7,500 @ $27.58 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4 | Johnson Paula A — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4 | Kornowski Sophie — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 16,142 @ $10.42 · Sale (S): 16,142 @ $27.61 · Option exercise (M): 16,142 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 2,439 @ $26.71 · Sale (S): 154 @ $27.09 · Sale (S): 30,304 @ $26.71 · Sale (S): 1,604 @ $27.09 | EDGAR |
| 2026-07-31 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 7,100 @ $27.31 · Sale (S): 400 @ $27.89 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 14,609 @ $10.42 · Sale (S): 13,409 @ $29.86 · Sale (S): 1,200 @ $30.34 · Option exercise (M): 14,609 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 2,593 @ $29.98 · Sale (S): 30,311 @ $29.95 · Sale (S): 1,597 @ $30.44 | EDGAR |
| 2026-07-01 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 7,500 @ $28.02 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 1,953 @ $26.00 · Sale (S): 2,040 @ $26 · Sale (S): 23,865 @ $26.05 | EDGAR |
| 2026-06-10 | 4 | Andrews Nancy C — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Hoppenot Herve — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Lim Jonathan E — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | SCHELLER RICHARD H — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | HOMCY CHARLES J — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 14,853 @ $10.42 · Sale (S): 13,253 @ $25.57 · Sale (S): 1,600 @ $26.36 · Option exercise (M): 14,853 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 6,090 @ $26.20 · Sale (S): 553 @ $26.24 | EDGAR |
| 2026-06-02 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 7,500 @ $26.34 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 4,504 @ $26.00 · Sale (S): 2,478 @ $26 · Sale (S): 25,582 @ $26.02 | EDGAR |
| 2026-05-18 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 15,000 @ $10.42 · Sale (S): 15,000 @ $26.22 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Coloma Jason V — Chief Executive Officer, Director | Sale (S): 1,822 @ $26 · Sale (S): 116 @ $26 | EDGAR |
| 2026-05-06 | 4 | Dandekar Atul — CSBO | Option exercise (M): 8,320 @ $10.42 · Option exercise (M): 5,985 @ $10.42 · Option exercise (M): 8,320 (derivative) @ $0 · Option exercise (M): 5,985 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | HOMCY CHARLES J — Director | Gift (G): 7,422 @ $0 | EDGAR |
| 2026-05-01 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 7,500 @ $25.37 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Bachrodt Amy — SVP, Finance | Option exercise (M): 2,500 @ $10.42 · Sale (S): 2,200 @ $29.32 · Sale (S): 300 @ $30.34 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 15,000 @ $10.42 · Sale (S): 11,352 @ $29.24 · Sale (S): 3,348 @ $30.06 · Sale (S): 300 @ $31.07 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 6,710 @ $29.26 · Sale (S): 790 @ $30.02 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | Kumar Neil — Director | Grant/award (A): 33,417 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 15,000 @ $10.42 · Sale (S): 6,161 @ $48.20 · Sale (S): 3,795 @ $49.32 · Sale (S): 5,044 @ $50.02 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 30,000 @ $10.42 · Sale (S): 29,652 @ $50.45 · Sale (S): 348 @ $51.02 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Bachrodt Amy — SVP, Finance | Option exercise (M): 5,000 @ $10.42 · Sale (S): 1,300 @ $44.44 · Sale (S): 3,700 @ $45.47 · Option exercise (M): 5,000 (derivative) @ $0 · Grant/award (A): 32,000 (derivative) @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Bernstein Harold — President, R&D & CMO | Grant/award (A): 48,000 (derivative) @ $0 · Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 3,739 @ $45.13 · Sale (S): 3,761 @ $45.72 · Option exercise (M): 7,500 (derivative) @ $0 · Grant/award (A): 38,000 (derivative) @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Tahir Misbah — Chief Financial Officer | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Courtney Phillips — GC and Corp. Secretary | Grant/award (A): 32,000 (derivative) @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Coloma Jason V — Chief Executive Officer, Director | Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Bachrodt Amy — SVP, Finance | Option exercise (M): 4,844 @ $10.42 · Option exercise (M): 156 @ $10.42 · Sale (S): 200 @ $44.15 · Sale (S): 4,064 @ $46.03 · Sale (S): 736 @ $46.63 · Option exercise (M): 4,844 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-04 | 4 | Bernstein Harold — President, R&D & CMO | Option exercise (M): 15,000 @ $10.42 · Sale (S): 600 @ $44.20 · Sale (S): 8,364 @ $45.89 · Sale (S): 5,936 @ $46.37 · Sale (S): 100 @ $47.23 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Dandekar Atul — CSBO | Option exercise (M): 7,500 @ $10.42 · Sale (S): 1,200 @ $43.18 · Sale (S): 3,500 @ $44.04 · Sale (S): 2,800 @ $45.01 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Bachrodt Amy — SVP, Finance | Option exercise (M): 2,497 @ $10.42 · Option exercise (M): 2,503 @ $10.42 · Sale (S): 5,000 @ $45.52 · Option exercise (M): 2,497 (derivative) @ $0 · Option exercise (M): 2,503 (derivative) @ $0 | EDGAR |
Recent 8-K events — Maze Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-25 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MAZE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →